Will Synthetic Biology Firm Amyris Post Net Income In 2024?

October 10, 2022

Pinnacle Associates Portfolio Manager Randy Baron explains to @Entrepreneur Magazine why #biotech Amyris (NASDAQ: AMRS) appears well-positioned to capitalize on a growing interest in environmentally #sustainable replacements for ingredients in #consumer products.

Important Disclosure

Thank you! Your submission has been received. A member of the Pinnacle team will be in touch shortly.

Oops! Something went wrong while submitting the form.